In general, pharmaceutical crystal forms are preferred by developers and regulatory authorities, because crystallization tends to afford highly pure products that are superior with respect to reproducibility and scalability (3). Moreover, a unique crystalline form may exhibit distinctive physicochemical properties and could in turn affect the dissolution, manufacturing, physical stability, permeability, and oral bioavailability of an API (4). Thus, it is apparent that selection of an appropriate crystal form for downstream development and processing is of primary importance in pharmaceutical development.